Kistler Tiffany Companies LLC boosted its holdings in shares of Celgene Co. (NASDAQ:CELG) by 14.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 7,641 shares of the biopharmaceutical company’s stock after buying an additional 937 shares during the period. Kistler Tiffany Companies LLC’s holdings in Celgene were worth $797,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. LGT Capital Partners LTD. grew its holdings in Celgene by 38.5% during the 4th quarter. LGT Capital Partners LTD. now owns 354,850 shares of the biopharmaceutical company’s stock valued at $37,032,000 after buying an additional 98,665 shares in the last quarter. Stock Yards Bank & Trust Co. grew its holdings in Celgene by 24.6% during the 4th quarter. Stock Yards Bank & Trust Co. now owns 147,819 shares of the biopharmaceutical company’s stock valued at $15,427,000 after buying an additional 29,140 shares in the last quarter. Trust Co grew its holdings in Celgene by 4.9% during the 3rd quarter. Trust Co now owns 18,484 shares of the biopharmaceutical company’s stock valued at $2,695,000 after buying an additional 860 shares in the last quarter. Bristol John W & Co. Inc. NY grew its holdings in Celgene by 13.2% during the 4th quarter. Bristol John W & Co. Inc. NY now owns 582,179 shares of the biopharmaceutical company’s stock valued at $60,756,000 after buying an additional 67,993 shares in the last quarter. Finally, Berson & Corrado Investment Advisors LLC grew its holdings in Celgene by 98.3% during the 4th quarter. Berson & Corrado Investment Advisors LLC now owns 19,417 shares of the biopharmaceutical company’s stock valued at $2,026,000 after buying an additional 9,625 shares in the last quarter. Institutional investors and hedge funds own 78.10% of the company’s stock.

CELG has been the subject of several research analyst reports. Cantor Fitzgerald set a $162.00 price target on Celgene and gave the company a “buy” rating in a report on Monday, October 16th. Jefferies Group restated a “buy” rating and set a $160.00 price target on shares of Celgene in a report on Monday, October 16th. BMO Capital Markets raised their price target on Celgene from $160.00 to $167.00 and gave the company a “positive” rating in a report on Tuesday, October 17th. Sanford C. Bernstein started coverage on Celgene in a report on Tuesday, October 17th. They set an “outperform” rating and a $162.00 price target for the company. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Celgene in a report on Monday, October 16th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $130.35.

Celgene Co. (NASDAQ CELG) opened at $92.51 on Monday. The company has a market capitalization of $69,583.77, a price-to-earnings ratio of 13.48, a PEG ratio of 0.66 and a beta of 1.49. The company has a debt-to-equity ratio of 2.29, a current ratio of 4.99 and a quick ratio of 4.80. Celgene Co. has a 1 year low of $88.32 and a 1 year high of $147.17.

Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.78 by $0.09. The firm had revenue of $3.48 billion during the quarter, compared to analyst estimates of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The business’s revenue for the quarter was up 16.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.61 EPS. research analysts anticipate that Celgene Co. will post 7.68 earnings per share for the current year.

In related news, insider Mark J. Alles purchased 3,260 shares of Celgene stock in a transaction dated Thursday, February 8th. The stock was purchased at an average cost of $91.90 per share, with a total value of $299,594.00. Following the transaction, the insider now owns 178,904 shares in the company, valued at approximately $16,441,277.60. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.95% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://theolympiareport.com/2018/02/12/celgene-co-celg-position-increased-by-kistler-tiffany-companies-llc.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.